Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Knowledge Synthesis Grant

McMaster University

$100,000.00

Management of Chronic Neuropathic Pain Syndromes: A Network Meta-Analysis

FY 2013-14

Summary
Chronic neuropathic pain (CNeP) results from lesions affecting the somatosensory system. There are several causes of CNeP, including diabetes and stroke. CNeP is common worldwide, affecting between 6-11% of the general population. Limited Canadian data from a 2009 survey of a random sample of Alberta's general population reported a 17.9% prevalence of CNeP. CNeP is associated with reduced health-related quality of life and substantial economic burden. There are a number of therapies available for managing CNeP, including non-pharmacological and pharmacological interventions. Randomized controlled trials (RCTs) exploring treatment for CNeP often compare pharmacological treatments against placebo and seldom against each other. As a result, there are few direct comparisons to help assess the relative effectiveness and safety of treatments. Existing systematic reviews addressing the management of CNeP focus focus on select therapies and/or isolated CNeP syndromes. Risk of bias assessment of studies within systematic reviews are variable, and reviewers have used instruments that have been criticized for being overly simplistic (e.g. Jadad), and/or assessed risk of bias on a per-study basis rather than by outcome. The only review of which we are aware that has explored the relative effectiveness of treatments for CNeP excluded many available management options, searched only four literature databases, and was restricted to English-language studies. The review authors did not report agreement between reviewers for the selection of eligible articles or risk of bias assessment. Their exploration of subgroup effects were very limited (unclear a priori hypotheses, authors did not specify the anticipated directions of the subgroup effects a priori, and they did not conduct formal tests of interactions). We propose to conduct a systematic review and multiple treatment comparison (network) meta-analyses of all treatments for CNeP, using the Cochrane risk of bias instrument to evaluate risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate confidence in the evidence. We will use the recommendations published by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), which has established patient-important endpoints for RCTs enrolling chronic pain patients, to inform the outcomes we will collect and present. All subjective decisions, including trial eligibility, and data collection will be done by teams of reviewers, independently and in duplicate, with assessments of the reproducibility of judgments. We will ensure interpretability of our results by presenting both risk differences and measures of relative effect for all outcomes reported and by presenting our findings with a GRADE Evidence Profile. We will conduct a limited number of a priori subgroup analyses consistent with current best practices. Our proposed review will guide evidence-based management of patients with CNeP and, facilitate updating of the Canadian Pain Society's guidelines for managing CNeP.
Program
Knowledge Synthesis Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
295468
Name
Busse Jason W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Knowledge Synthesis Grant
Projecttitle
Management of Chronic Neuropathic Pain Syndromes: A Network Meta-Analysis
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Chronic Neuropathic Pain; Evidence Synthesis; Network Meta-Analysis; Systematic Review
Abstract
<html> <body>Chronic neuropathic pain (CNeP) results from lesions affecting the somatosensory system. There are several causes of CNeP, including diabetes and stroke. CNeP is common worldwide, affecting between 6-11% of the general population. Limited Canadian data from a 2009 survey of a random sample of Alberta's general population reported a 17.9% prevalence of CNeP. <br> <br> CNeP is associated with reduced health-related quality of life and substantial economic burden. There are a number of therapies available for managing CNeP, including non-pharmacological and pharmacological interventions. Randomized controlled trials (RCTs) exploring treatment for CNeP often compare pharmacological treatments against placebo and seldom against each other. As a result, there are few direct comparisons to help assess the relative effectiveness and safety of treatments. <br> <br> Existing systematic reviews addressing the management of CNeP focus focus on select therapies and/or isolated CNeP syndromes. Risk of bias assessment of studies within systematic reviews are variable, and reviewers have used instruments that have been criticized for being overly simplistic (e.g. Jadad), and/or assessed risk of bias on a per-study basis rather than by outcome. <br> <br> The only review of which we are aware that has explored the relative effectiveness of treatments for CNeP excluded many available management options, searched only four literature databases, and was restricted to English-language studies. The review authors did not report agreement between reviewers for the selection of eligible articles or risk of bias assessment. Their exploration of subgroup effects were very limited (unclear <em>a priori</em> hypotheses, authors did not specify the anticipated directions of the subgroup effects <em>a priori</em>, and they did not conduct formal tests of interactions). <br> <br> We propose to conduct a systematic review and multiple treatment comparison (network) meta-analyses of all treatments for CNeP, using the Cochrane risk of bias instrument to evaluate risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate confidence in the evidence. We will use the recommendations published by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), which has established patient-important endpoints for RCTs enrolling chronic pain patients, to inform the outcomes we will collect and present. All subjective decisions, including trial eligibility, and data collection will be done by teams of reviewers, independently and in duplicate, with assessments of the reproducibility of judgments. We will ensure interpretability of our results by presenting both risk differences and measures of relative effect for all outcomes reported and by presenting our findings with a GRADE Evidence Profile. We will conduct a limited number of <em>a priori</em> subgroup analyses consistent with current best practices. Our proposed review will guide evidence-based management of patients with CNeP and, facilitate updating of the Canadian Pain Society's guidelines for managing CNeP.</body> </html>
Competitiondate
201310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Busse, Jason W; Levine, Mitchell A; Guyatt, Gordon H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~